Veradermics Q3 net loss widens to $21 million

Bitget2026/11/10 12:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Veradermics’ third-quarter 2026 net loss widened to $21 million from a year earlier.
General and administrative expenses rose to $12.7 million, while research and development spending fell 11% to $16.08 million year over year.
Cash, cash equivalents and marketable securities totaled $798.4 million at September 30, expected to fund operations into 2030.
VDPHL01 delivered positive Phase 3 Study 304 results and positive 12-month Phase 2/3 Study 302 data in male pattern hair loss.
Topline results from registration-directed Study 306 in female pattern hair loss remain on track for the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611100730BIZWIRE_USPR_____20261110_BW316485) on November 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Veradermics Q3 net loss widens to $21 million

You may also like

Crypto prices